NeoPharm (NEOL) Requests Hearing for Continued Listing on NASDAQ
More News related to NEOL
- NeoPharm Names Dr. Aquilur Rahman as President and CEO
- NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally Advanced or Metastatic Pancreatic Cancer Patients as a Frontline Treatment
- NeoPharm (NEOL) Posts Q3 Loss of $0.06
- NeoPharm, Inc. Announces Third Quarter 2009 Financial Results and Clinical Trials Update
- NeoPharm (NEOL) Requests Hearing for Continued Listing on NASDAQ
More News related to Corporate News
- Mexican Restaurants (CASA) Posts Q3 Loss of $0.07, Better Y/Y; Revs Down
- Cosi (COSI) Posts Q3 Loss of $0.06, Beats By 2c
- Enterprise GP Holdings (EPE) Posts Q3 EPS of $0.18, Misses Views
- Mindray Medical (MR) Tops Q3 EPS by 6c; Revs Light
- Neenah Paper (NP) Tops Q3 Views
NeoPharm, Inc. (NASDAQ: NEOL) intends to request a hearing before the NASDAQ Listing Qualifications Panel at which it will request continued listing on The NASDAQ Stock Market pending completion of its plan to regain compliance with the $1.00 bid price requirement, as set forth in NASDAQ Marketplace Rule 4310(c)(4). As previously announced on June 12, 2008, the NASDAQ Listing Qualifications Staff previously determined to grant the Company's request to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Market. Based on discussions with the Staff, the Company believed it would be eligible for an additional 180-day grace period to regain compliance with the $1.00 bid price requirement, through December 20, 2008.[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
